Literature DB >> 8622450

Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.

J Satsangi1, K I Welsh, M Bunce, C Julier, J M Farrant, J I Bell, D P Jewell.   

Abstract

BACKGROUND: Despite strong evidence implicating immune dysfunction and genetic predisposition in the pathogenesis of the chronic inflammatory bowel diseases Crohn's disease and ulcerative colitis, the importance of the genes of the major histocompatibility complex remains uncertain. We have investigated the contribution of HLA DRB1 and DQB genes by the strategies of non-parametric linkage analysis (affected sibling pair method) as well as association study. The relation between genotype and phenotype was examined in detail.
METHODS: For linkage analysis 74 families in whom two or more siblings had inflammatory bowel disease were studied. A total of 83 affected sibling pairs were involved: in 42 pairs both siblings had Crohn's disease; in 29 both had ulcerative colitis; in 12 one sibling had Crohn's disease, the other ulcerative colitis. For the association study there were 175 patients with ulcerative colitis, 173 with Crohn's disease, and 472 controls. Details of sex, age of onset, disease extent, and family history were analysed. 24 patients with ulcerative colitis and 92 with Crohn's disease required surgery for refractory disease. HLA DRB1 and DQB1 gene-typing was performed by polymerase chain reaction with sequence-specific primers.
FINDINGS: In ulcerative colitis, the sharing of alleles among affected sibling pairs provided evidence for linkage with DRB1 locus (p = 0.017, chi2 = 5.32). Of 29 affected sibling pairs studied, only one pair shared no DRB1 DQB haplotypes. 15 shared two DRB DQB haplotypes. In contrast, no linkage was noted for Crohn's disease (42 sibling pairs; p = 0.30, chi2 = 0.16) or for inflammatory bowel disease overall (83 sibling pairs, p = 0.16, chi2 = 2.28). In the association study the rare DRB1*103 (8.3% vs 3.2% in controls) and DRB1*12 (8.6% vs 2.1% in controls) alleles were associated with ulcerative colitis (p = 0.0074, chi2 = 7.22, odds ratio OR = 2.9 [95% CI 1.3-6.4] and p = 0.0056, chi2 = 12.63, OR = 4.33 [1.8-11.0] respectively). No association with alleles representing DR2 (p = 0.55, chi2 = 0.34) was noted. No overall association was seen in Crohn's disease. In ulcerative colitis, the frequency of DRB1*0301 DQB*0201 (DR3 DQ2) was reduced in females (9.8% vs 26.3% in controls, p = 0.037, chi2 = 8.39 OR = 0.34 [0.15-0.71]), particularly in those with distal disease (2.3%, p = 0.001 vs controls, chi2 = 11.35, OR = 0.07 [0.00-0.39]). In both males and females, the DR3 DQ2 haplotype was predictive of extensive ulcerative colitis (32.9% vs 10.7% in distal disease, p < 0.01, chi2 = 10.94, OR 4.09 [1.70-10.6]) but not of need for surgery (p = 0.93, chi2 = 0.01).
INTERPRETATION: These data provide strong evidence for genetic heterogeneity in inflammatory bowel disease. Genes of the major histocompatibility complex are implicated as important inherited determinants of susceptibility to ulcerative colitis and may also influence the pattern of disease. In Crohn's disease, important susceptibility genes are likely to exist outside the HLA region.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622450     DOI: 10.1016/s0140-6736(96)90734-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  70 in total

1.  HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis.

Authors:  P C Stokkers; P H Reitsma; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease.

Authors:  M M Kosiewicz; C C Nast; A Krishnan; J Rivera-Nieves; C A Moskaluk; S Matsumoto; K Kozaiwa; F Cominelli
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 3.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 4.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

5.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

6.  Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population.

Authors:  J Matsuzawa; K Sugimura; Y Matsuda; M Takazoe; K Ishizuka; T Mochizuki; S S Seki; O Yoneyama; H Bannnai; K Suzuki; T Honma; H Asakura
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 7.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

Review 8.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

9.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

10.  Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives.

Authors:  L Biancone; G Monteleone; R Marasco; F Pallone
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.